Evidence map›Paper›PMID 33766651›Full record

ReviewSeminars in cancer biology2022

Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer.

Geetanjali Saini, Shriya Joshi, Chakravarthy Garlapati, Hongxiao Li, Jun Kong, Jayashree Krishnamurthy, Michelle D Reid, Ritu Aneja

Abstract readReview
In one paragraph

Review in Seminars in cancer biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Review
  2. Review
  3. Berberine shows potential in mitigating PMApoptosis : an international journal on programmed cell death · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Polyploidy and Senescence of Cancer Cells: Impact of Cell Fusion.Advances in experimental medicine and biology · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Geetanjali SainiDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Shriya JoshiDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Chakravarthy GarlapatiDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Hongxiao LiDepartment of Mathematics and Statistics, Georgia State University, Atlanta, GA, USA; Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jun KongDepartment of Mathematics and Statistics, Georgia State University, Atlanta, GA, USA; Department of Computer Science, Georgia State University, Atlanta, GA, USA; Department of Computer Science, Emory University, Atlanta, GA, USA.
Jayashree KrishnamurthyDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Michelle D ReidDepartment of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Ritu AnejaDepartment of Biology, Georgia State University, Atlanta, GA, USA. Electronic address: raneja@gsu.edu.

Funding

HSET as a racial disparity biomarker for TNBC patientsR01CA239120 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANEJA, RITU · 2019 to 2024
$3.0M
Computational pathology software for integrative cancer research with three-dimensional digital slidesU01CA242936 · NCI · GEORGIA STATE UNIVERSITY · PI KONG, JUN, WANG, FUSHENG · 2019 to 2021
$1.1M
NCI NIH HHS R01 CA239120NCI NIH HHS U01 CA242936
6 · The paper itself

Abstract

Although polyploid cells were first described nearly two centuries ago, their ability to proliferate has only recently been demonstrated. It also becomes increasingly evident that a subset of tumor cells, polyploid giant cancer cells (PGCCs), play a critical role in the pathophysiology of breast cancer (BC), among other cancer types. In BC, PGCCs can arise in response to therapy-induced stress. Their progeny possess cancer stem cell (CSC) properties and can repopulate the tumor. By modulating the tumor microenvironment (TME), PGCCs promote BC progression, chemoresistance, metastasis, and relapse and ultimately impact the survival of BC patients. Given their pro- tumorigenic roles, PGCCs have been proposed to possess the ability to predict treatment response and patient prognosis in BC. Traditionally, DNA cytometry has been used to detect PGCCs.. The field will further derive benefit from the development of approaches to accurately detect PGCCs and their progeny using robust PGCC biomarkers. In this review, we present the current state of knowledge about the clinical relevance of PGCCs in BC. We also propose to use an artificial intelligence-assisted image analysis pipeline to identify PGCC and map their interactions with other TME components, thereby facilitating the clinical implementation of PGCCs as biomarkers to predict treatment response and survival outcomes in BC patients. Finally, we summarize efforts to therapeutically target PGCCs to prevent chemoresistance and improve clinical outcomes in patients with BC.

Indexed as

Breast NeoplasmsArtificial IntelligenceCell Line, TumorFemaleHumansNeoplasm Recurrence, LocalPolyploidyTumor MicroenvironmentArtificial intelligenceBreast cancerChemo resistancePatient prognosisPolyploid giant cancer cell

Identifiers

PMID33766651
PMCPMC8672208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.